anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Southern rice black-streaked dwarf virus disease (SRBSDVD) is the most destructive viral disease in rice. In order to breeding resistant cultivars, Insertion-Deletion (InDel) markers were developed linked to OsAP47, the first isolated major resistance gene against SRBSDVD. Marker-assisted selection (MAS) was conducted to introduce this gene into the commercial variety. A rice line carrying homozygous resistance allele of OsAP47 was selected and named Kanghei No. 201 (KH201). Evaluated by artificial inoculation, KH201 showed significantly higher resistance than the recurrent parent Suxiu No.867 (SX867). And no significant differences were detected for KH201 in the yield-related components, including spikelets per panicle (SPP), ripened grains per panicle (RGPP), 1000-grain weight (TGW) and panicles per square meter (PPSM), leading to stable theoretical yield. The results indicated that introgression of OsAP47 improved rice resistance and can avoid yield losses produced by SRBSDVD. KH201 was demonstrated as a resistance material that could be used in rice breeding.
FIELD: cosmetics. SUBSTANCE: cosmetic compositions comprise in cosmetically acceptable medium at least one special amphoteric starch and at least one cationic conditioner taken among surface-active substances of ammonium quaternary salts, cyclopolymers of alkyldiallylamine or dialkyldiallyl ammonium, cationic polymers containing ammonium quaternary groups in main chain and cationic silicones. Invention relates also to method of treatment of keratin fibers, for example, hair using the above-mentioned cosmetic compositions. Invention allows to eliminate problems associated with using compositions for hair based on conditioners, for example, weighting, insufficient smoothness and softness of hair in retention of other positive cosmetic properties that are associated with conditioner- -base composition. Invention can be used for washing and care with keratin materials, for example, hair, skin, eyelash, eyebrow, nails, lips and skin of head hairy part. EFFECT: improved and valuable properties of compositions. 19 cl, 1 tbl
Patients with sepsis differ in their clinical presentations and immune dysregulation in response to infection, but the fundamental processes that determine this heterogeneity remain elusive. Here, we aim to understand which types of immune dysregulation characterize patients with sepsis. To that end, we investigate sepsis pathogenesis in the context of two transcriptional states: one represents the immune response to eliminate pathogens (resistance, R) and the other is associated with systemic inflammation (SI). We find that patients with sepsis share a molecular fingerprint of a low R-to-SI balance-i.e., a low R relative to the level of SI. Differences between patients with sepsis are explained by the wide diversity of R and SI states that fall under this fingerprint, such as patients with high SI, patients with low R, or both. We show how this R/SI framework can be used to guide patient stratification that is relevant to disease prognosis and management, outperforming existing classifications of sepsis.
The multidose vials are formulated with benzyl alcohol. Do not administer PROCRIT from multidose vials, or PROCRIT from single-dose vials admixed with bacteriostatic saline containing benzyl alcohol, to pregnant women. When therapy with PROCRIT is needed during pregnancy, use a benzyl alcohol-free formulation [see Dosage and Administration (2) and Contraindications (4)].

Pregnancy Category C (single-dose vials only)

There are no adequate and well-controlled studies of PROCRIT use during pregnancy. There are limited data on PROCRIT use in pregnant women. In animal reproductive and developmental toxicity studies, adverse fetal effects occurred when pregnant rats received epoetin alfa at doses approximating the clinical recommended starting doses. Single-dose formulations of PROCRIT should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. 

There are reports of at least 33 pregnant women with anemia alone or anemia associated with severe renal disease and other hematologic disorders who received PROCRIT. Polyhydramnios and intrauterine growth restriction were reported in women with chronic renal disease, which is associated with an increased risk for these adverse pregnancy outcomes. There was 1 infant born with pectus excavatum and hypospadias following exposure during the first trimester. Due to the limited number of exposed pregnancies and multiple confounding factors (such as underlying maternal conditions, other maternal medications, and gestational timing of exposure), these published case reports and studies do not reliably estimate the frequency or absence of adverse outcomes.

When healthy rats received PROCRIT at doses of 100 Units/kg/day during mating and through early pregnancy (dosing stopped prior to organogenesis), there were slight increases in the incidences of pre- and post-implantation loss, and a decrease in live fetuses. This animal dose level of 100 Units/kg/day may approximate the clinical recommended starting dose, depending on the treatment indication. When healthy pregnant rats and rabbits received intravenous doses of up to 500 mg/kg/day of PROCRIT only during organogenesis, no teratogenic effects were observed in the offspring.

When healthy pregnant rats received PROCRIT at doses of 500 Units/kg/day late in pregnancy (after the period of organogenesis), offspring had decreased number of caudal vertebrae and growth delays [see Nonclinical Toxicology (13.3)].
PROBLEM TO BE SOLVED: To obtain the subject medicine inhibiting tyrosinase activity by containing a 4-substituted benzoic acid or its salt. SOLUTION: This medicine is composed of a compound of the formula (R is an electron-donating group) or its salt. As the above electron-donating group, an alkoxy, an alkyl, methoxy and isopropyl are illustrated. As the compound of the formula, e.g. 4-methoxybenzoic acid, 4-ethoxybenzoic acid and 4- isopropylbenzoic acid are illustrated. Further, this medicine may be used along with a necessary amount of L-ascorbic acid (vitamin C) and as the result, inhibitory effect for tyrosinase activity becomes more effective and the term inhibiting the whole reaction of melamine formation is prolonged.  Since this medicine is low toxic even in independent use and possesses inhibitory action for tyrosinase activity, it is effective as a, component of preparation for external use for skin having skin whitening effect, a component of inhibitor for inflammation and a medicinal component for preventing browning of foods and drinks.
Eliglustat plus imiglucerase for three years, at the dose of enzyme replacement therapy received before enrollment. After Week 52, Cohort 2 patients will switch to eliglustat monotherapy for the remainder of the study if the desired clinical response has been achieved.
Chronic myeloid leukemia (CML) is a hematopoietic malignancy driven by the fusion gene BCR::ABL1. Drug resistance to tyrosine kinase inhibitors (TKIs), due to BCR::ABL1 mutations and residual leukemia stem cells (LSCs), remains a major challenge in CML treatment. Here, we revealed the requirement of the vitamin D receptor (VDR) in the progression of CML. VDR was upregulated by BCR::ABL1 and highly expressed in CML cells. Interestingly, VDR knockdown inhibited the proliferation of CML cells driven by both BCR::ABL1 and TKI-resistant BCR::ABL1 mutations. Mechanistically, VDR transcriptionally regulated DDIT4 expression; reduced DDIT4 levels upon VDR knockdown triggered DNA damage and senescence via p53 signaling activation in CML cells. Furthermore, VDR deficiency not only suppressed tumor burden and progression in primary CML mice but also reduced the self-renewal capacity of CML-LSCs. Together, our study demonstrated that targeting VDR is a promising strategy to overcome TKI resistance and eradicate LSCs in CML.
PROBLEM TO BE SOLVED: To obtain the subject new compound having a methylene chain between functional groups and having ether bond and anionic ester group in long- chain alkyl chain part and having wide application range and excellent in general-purpose properties as a component of liposome, etc., or as drug delivery system agent for chemical modification. SOLUTION: This compound is represented by formula I [R<1> and R<2> are each an alkyl or a group obtained by substituting carbon-carbon single bond of an alkyl with carbon-carbon double bond; R<3> is a lower alkyl or hydrogen; (n) is >=2], e.g. 7,8-dioleyloxy octanoic acid. The compound is obtained by reacting, e.g. a compound of formula II with an alkylating agent such as an alkyl chloride to afford 1,2-dioldialkyl ether, hydroboronizing a terminal carbon of the terminal olefin thereof with a hydroboronizing agent such as diborane and subjecting the reaction product to oxidation reaction with preferably hydrogen peroxide to afford a terminal alcohol of formula III and subjecting the compound of formula III to oxidation reaction with e.g. Jones reagent.
Both groups will receive the standard care provided at the long-term care home. The intervention group will receive the addition of directed occupational therapy intervention provided by student occupational therapists for up to 30 minutes, five days a week. At present, no decisive evidence exists that this intervention being tested will be superior to the standard of care.
BACKGROUND: Hypereosinophilic syndrome (HES) is a rare hematological disorder, characterized by blood and tissue eosinophilia, causing tissue damage and dysfunction. The onset of the disease is generally asymptomatic, being discovered incidentally. The objective of this article is to illustrate the rare clinical presentation in patients with chronic kidney disease.
CLINICAL CASE: A 69-year-old male patient, with a history of type 2 diabetes and high blood pressure, was admitted to the internal medicine service with wasting syndrome under study, multiple urticarial skin lesions and peripheral blood cytopenias. During the approach to him, eosinophilia of more than 5.0 × 109 / L was evidenced, a bone marrow aspirate was performed, which revealed eosinophilic infiltration with dysplasia, biopsy of dermal lesions with mixed cellular infiltrate with a predominance of eosinophils; With the above, the diagnosis of idiopathic HES is made, after the exclusion of other evident eosinophilia etiologies. Systemic steroid treatment was started.
CONCLUSIONS: Eosinophilic disorders represent a heterogeneous group of rare conditions, with multiple clinical manifestations, predominantly dermatological. An important association with the development of chronic kidney disease is reported, so a comprehensive approach must be carried out, with the aim of achieving an etiological diagnosis that allows early treatment and improves survival.
ZERBAXA does not contain a bacteriostatic preservative. Aseptic technique must be followed in preparing the infusion solution.

Preparation of doses:

Constitute each vial of ZERBAXA with 10 mL of sterile water for injection or 0.9% Sodium Chloride for Injection, USP and gently shake to dissolve. The final volume is approximately 11.4 mL per vial. Caution: The constituted solution is not for direct injection.

To prepare the required dose, withdraw the appropriate volume determined from Table 4 from the reconstituted vial(s). Add the withdrawn volume to an infusion bag containing 100 mL of 0.9% Sodium Chloride for Injection, USP or 5% Dextrose Injection, USP. For doses above 1.5 g, reconstitute a second vial in the same manner as the first one, withdraw an appropriate volume (per Table 4), and add to the same infusion bag. Discard unused portion.

Inspect drug products visually for particulate matter and discoloration prior to use. ZERBAXA infusions range from clear, colorless solutions to solutions that are clear and slightly yellow. Variations in color within this range do not affect the potency of the product.
BACKGROUND AND OBJECTIVES: Whether the outcome of patients with spontaneous intracerebral hemorrhage (ICH) differs depending on the type of hospital where they are admitted is uncertain. The objective of this study was to determine influence of hospital type at admission (telestroke center [TSC], primary stroke center [PSC], or comprehensive stroke center [CSC]) on outcome for patients with ICH. We hypothesized that outcomes may be better for patients admitted to a CSC.
METHODS: This is a multicenter prospective observational and population-based study of a cohort of consecutively recruited patients with ICH (March 2020-March 2022). We included all patients with spontaneous ICH in Catalonia (Spain) who had a pre-ICH modified Rankin scale (mRS) score of 0-3 and who were admitted to the hospital within 24 hours of onset. We compared patients admitted to a TSC/PSC (n = 641) or a CSC (n = 1,320) and also analyzed the subgroup of patients transferred (n = 331) or not transferred (n = 310) from a TSC/PSC to a CSC. The main outcome was the 3-month mRS score obtained by blinded investigators. Outcomes were compared using adjusted ordinal logistic regression to estimate the common odds ratio (OR) and 95% CI for a shift in mRS scores. A propensity score matching (PSM) analysis was performed for the subgroup of transferred patients.
RESULTS: Relevant data were obtained from 1961 of a total of 2,230 patients, with the mean (SD) age of 70 (14.1) years, and 713 (38%) patients were women. After adjusting for confounders (age, NIH Stroke Scale score, intraventricular hemorrhage, hematoma volume, and pre-ICH mRS score), type of hospital of initial admission (CSC vs TSC/PSC) was not associated with outcome (adjusted common OR 1.13, 95% CI 0.93-1.38). A PSM analysis indicated that transfer to a CSC was not associated with more favorable outcomes (OR 0.77, 95% CI 0.55-1.10; p = 0.16).
DISCUSSION: In this population-based study, we found that, after adjusting for confounders, hospital types were not associated with functional outcomes. In addition, for patients who were transferred from a TSC/PSC to a CSC, PSM indicated that outcomes were similar to nontransferred patients. Our findings suggest that patient characteristics are more important than hospital characteristics in determining outcome after ICH.
TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov Identifier: NCT03956485.
In a thorough QT study, citalopram hydrobromide was found to be associated with a dose-dependent increase in the QTc interval (see WARNINGS, QT-Prolongation and Torsade de Pointes). 

Electrocardiograms from citalopram hydrobromide (N = 802) and placebo (N = 241) groups were compared with respect to outliers defined as subjects with QTc changes over 60 msec from baseline or absolute values over 500 msec post-dose, and subjects with heart rate increases to over 100 bpm or decreases to less than 50 bpm with a 25% change from baseline (tachycardic or bradycardic outliers, respectively). In the citalopram hydrobromide group 1.9% of the patients had a change from baseline in QTcF > 60 msec compared to 1.2% of the patients in the placebo group. None of the patients in the placebo group had a post-dose QTcF > 500 msec compared to 0.5% of the patients in the citalopram hydrobromide group. The incidence of tachycardic outliers was 0.5% in the citalopram hydrobromide group and 0.4% in the placebo group. The incidence of bradycardic outliers was 0.9% in the citalopram hydrobromide group and 0.4% in the placebo group.
PURPOSE:To obtain a gel hair cosmetic especially suitable as a hair rinse, by using an amino acid alkyl ester salt such as glycine cetyl ester hydrochloride, a straight-chain saturated alcohol, and a condensate of a fatty acid and polypeptide, at specific ratios. CONSTITUTION:The objective hair cosmetic contains (A) one or more amino acid alkyl ester salts and/or their derivatives (surface active agents having extremely high safety) of formula (R1 is 16-22C long-chain alkyl; R2 is 1-4C alkyl; R3 is H or CH3; X is halogen, sulfate group, acetate group, or citrate group) obtained by condensing an amino acid or its derivative with a higher alcohol and neutralizing the product with an acid, (B) a 14-22C straight-chain saturated alcohol (e.g. cetyl alcohol) and (C) a condensation product of a 8-22C fatty acid and a polypeptide. The amount of the components (A), (B) and (C) are 0.5-4.0wt%, 0.7-5.0wt% and 0.1-3.0wt%, respectively. EFFECT:The agent moistens and collects the hair without giving stickiness. It is also effective to improve the loosening property of the hair and is non-irritant to the skin.
Cyclophosphamide 60 mg/kg/d by vein (IV) daily for 2 days followed by fludarabine 25 mg/m\^2 IV daily for 5 days before T cell infusion. The day after chemotherapy up to 5 x 10\^10 T cells IV infusion. Interleukin-2 90 minutes after T cell infusion at a dose of 100,000 IU/kg as IV bolus over 15 minute period every 8-hours for up to 14 doses.
Atherosclerosis (AS) is the common pathophysiological basis of various cardiovascular diseases and the leading cause of death from cardiovascular disease worldwide. When the body is in a hypoxic environment, enhanced oxidative stress and significant accumulation of reactive oxygen species (ROS) in tissue cells exacerbate the inflammatory response, resulting in increased release of myeloperoxidase (MPO), catalyzing the formation of large quantities of hypochlorous acid (HOCl), further oxidative modification of low-density lipoprotein (LDL), and exacerbating the formation and progression of atherosclerotic plaques. The MAPK signaling pathway is important in oxidative stress-mediated promotion of atherogenesis. MPO -/- mice were used in this study to establish a hypoxia model simulating 5000 m altitude and a Western high-fat diet-induced atherosclerosis model for 12 weeks. Exploring the role of MPO in the atherosclerotic process in hypoxic mice by observing the MAPK signaling pathway to provide a therapeutic target for the prevention and treatment of hypoxic atherosclerotic disease in the plateau. We found that hypoxia promotes the formation of atherosclerosis in mice, and the mechanism may be that increased MPO in vivo promotes an inflammatory response, which plays a crucial role in the formation of atherosclerosis. In addition, hypoxia further exacerbates plaque instability by activating the MAPK signaling pathway to upregulate vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP9), which in turn promotes angiogenesis within the plaque. Therefore, a potential target for preventing and treating hypoxic atherosclerotic disease is the inhibition of MPO.
The invention discloses a new application of triptolide in preventing and treating osteoporosis. Along with aging of population, the morbidity of osteoporosis quickly increases, and the osteoporosis has become an important disease jeopardizing human health, and brings about huge social and economic burden to the world. Although related specialists and scholars at home and abroad attach great importance to osteoporosis, no effective therapeutic drug can treat the disease. The in-vivo test detects that the triptolide has obvious effect on preventing osteoporosis. The osteological pharmacological mechanism is to inhibit the bone conversion rate, reduce the bone loss and increase the bone density. The triptolide is an ideal drug for preventing osteoporosis.
From an initial 0.1% capsaicin (Sigma-Aldrich, St. Louis, MO) stock solution in 95% ethanol; we prepared solutions with 33, 66, 99, 132 and 165 μMol/ml by diluting the stock solution with distilled water. We consecutively tested 6 participants for each dose of capsaicin alternating the stimulated side of the palate.
PURPOSE: To evaluate time trends in distance and near vision at the national and regional levels during 2000-2017 in Finland.
METHODS: We used three cross-sectional, nationwide health examination surveys representing the Finnish adult population aged 30 years or older in 2000, 2011 and 2017. Bilateral, habitual distance and near visual acuity (VA) were measured in all three surveys.
RESULTS: The prevalence of good distance vision (VA ≥ 1.0) increased from 76.7% to 81.3% during 2000-2017 while the prevalence of weak or worse distance vision (VA ≤ 0.5) decreased from 7.6% to 3.7%. The improvements were largest among those aged 85 years and older: the prevalence of distance VA ≤ 0.5 decreased from 71.8% to 28.3%. Near vision showed improvement to a lesser extent in the total population; nevertheless, among those aged 85 years and older the prevalence of weak or worse near vision (VA ≤ 0.5) decreased from 62.3% to 27.1%. A similar positive time trend was observed in all main regions of Finland, and differences between urban and rural regions were small.
CONCLUSION: During the past two decades, the overall vision level has improved among the adult population. This is explained mostly by a positive shift from lower to higher vision levels among older age groups, indicating that people live longer with good or adequate vision. This positive trend showed remarkable similarity throughout different regions in Finland, highlighting the importance of equal and accessible eye care throughout the country.
The experiment protocol involves a maximum of ten sessions and will take two or three hours for each session. Baseline data will be collected before the first session for both overground and treadmill walking. During this session, the sound level will be adjusted based on the feedback received from the users. The researcher will ask the comfortable sound level to the participant before starting the experiment. Training will be conducted on the treadmill with the cable-actuated device for about 20 minutes. When the cables were removed, participants walked on the treadmill for 4 minutes during the post-training session. During training and post-training, participants will be exposed to feedback while walking on the treadmill. After treadmill walking, CP participants will be asked to take a ten-minute break and then practice overground walking for two minutes with auditory feedback (type A) and without it (type B). Effects of 3 different types of auditory feedback will be explored namely, rhythmic sounds, movement sonification, and sound notifying erroneous gait. Group A participants will be further divided into groups depending on the type of auditory feedback that will be provided. Participants will participate in a maximum of 10 sessions, two or three times a week. Before the first and after the last training, participants will be evaluated for functional gait assessment, 6-min-walk, leg strength using a dynamometer, and Modified Ashworth test by a physical therapist.
Single arm trial in patients with established RA who achieved clinical remission with subcutaneous injection of adalimumab in combination with MTX (methotrexate). Patients will undergo a tapering strategy based only on the clinical status (flare /no flare) during 12 months.